MP-15.20 Long-Term Follow-Up of Cisplatin Combination Chemotherapy in Patients with Disseminated Nonseminomatous Testicular Tumors: Is a Post-Chemotherapy Retroperitoneal Lymphadenectomy Needed After Complete Remission?

Argirovic, D.; Argirović, A.

doi:10.1016/j.urology.2011.07.364

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrary to reports by Fizazi et al 19 , the IGCCG risk category did not affect the overall prognosis after rPLa, but it is possible that a higher proportion of men initially with IGCCCG poor-risk disease had rapid disease progression and never had rPLa, and therefore were not included in this study 10 . The use of secondline chemotherapy predict higher probability of relapse and lower dss after surgery.…”

Section: Discussioncontrasting

confidence: 57%

See 1 more Smart Citation

Outcome analysis of postchemotherapy retroperitoneal lymphadenectomy in men with intermediate- and poor- risk nonseminomatous testicular tumors

Argirovic¹,

Argirović²

2011

Mat Med

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 57%

“…While many advocate a policy of surveillance for such small masses, the consequence of residual viable GCT is disease progression 10,11 . Furthermore, the histological potential of unresected teratoma remains unpredictable.…”

Section: Discussionmentioning

confidence: 99%

Outcome analysis of postchemotherapy retroperitoneal lymphadenectomy in men with intermediate- and poor- risk nonseminomatous testicular tumors

Argirovic¹,

Argirović²

2011

Mat Med

View full text Add to dashboard Cite

show abstract

“…However, our study demonstrated that a patient obtaining a CR after 1st line chemotherapy can be safely observed without PC-RPLA. Relapses are rare and potentially curable with further therapy 13 . Currently predictive models and imaging modalities cannot reliably predict the finding of fibrosis at PC-RPLA.…”

Section: Introductionmentioning

confidence: 99%

Can we predict the presence of teratoma in the retroperitoneum before post-chemotherapy retroperitoneal lymphadenectomy?

Argirović¹,

Argirović²

2015

Mat Med

View full text Add to dashboard Cite

The biological potential of teratoma remains unpredictable, therefore identifying its presence in the retroperitoneum remains important. We evaluated patients undergoing post-chemothe rapy retroperitoneal lymphadenectomy (PC-RPLA) for nonseminomatous testicular tumors (NSTT), to determine predictors of teratomatous elements in the retroperitoneum. We identified 161 patients from 1982 to 2005 who underwent PC-RPLA for metastatic NSTT. Multiple clinical and pathological variables were reviewed from out RPLA database. Of the 161 patients in our series, 112 (70%) received only induction chemotherapy and 49 (30%) required 2nd line chemotherapy. Studies of retroperitoneal pathology demonstrated the presence of fibrosis in 44 (27%), teratoma in 82 (51%) and vital carcinoma in 35(22%).Among 82 patients (51%) with finding of teratomatous elements at PC-RPLA, we revealed the presence ofmature teratoma in 85%, immature teratoma in 12% and teratoma with malignant transformation in 3%. Of the 99 patients (61%) with teratomatous elements in the primary NSTT, 61 (62%) had teratoma at PC-RPLA. Even in the absence of teratoma in the primary NSTT, teratoma was present in the retroperitoneum in 21 of 62 patients (32%)(p<0.0001). All patients had normal values of serum tumor markers (STM) at PC-RPLA. Post-chemotherapy retroperitoneal residual mass measuring <2 cm, from 2.1-5.0 cm and > 5 cm in diameter occured in 30%, 52% and 55%, respectively. By multivariate analysis , teratoma in the orchiectomy specimen (p<0.005), relative change in nodal size before and after chemotherapy (p<0.005), and no requirement for 2nd line chemotherapy (p=0.33) were independent predictors for the presence of the teratoma in the retroperitoneum. Teratoma remains

show abstract

MP-15.20 Long-Term Follow-Up of Cisplatin Combination Chemotherapy in Patients with Disseminated Nonseminomatous Testicular Tumors: Is a Post-Chemotherapy Retroperitoneal Lymphadenectomy Needed After Complete Remission?

Cited by 2 publications

References 0 publications

Outcome analysis of postchemotherapy retroperitoneal lymphadenectomy in men with intermediate- and poor- risk nonseminomatous testicular tumors

Outcome analysis of postchemotherapy retroperitoneal lymphadenectomy in men with intermediate- and poor- risk nonseminomatous testicular tumors

Can we predict the presence of teratoma in the retroperitoneum before post-chemotherapy retroperitoneal lymphadenectomy?

Contact Info

Product

Resources

About